Journal of Neuroimmunology
Volume 217, Issue 1 , Pages 46-50 , 10 December 2009

Polyclonal immunoglobulins (IVIg) induce expression of MMP-9 in microglia

  • R. Pul

      Affiliations

    • Dept. of Neurology, Hannover Medical School, Hannover, Germany
    • ,
  • T. Kopadze

      Affiliations

    • Dept. of Neurology, Heinrich-Heine-Universität, Düsseldorf, Germany
    • ,
  • T. Skripuletz

      Affiliations

    • Dept. of Neurology, Hannover Medical School, Hannover, Germany
    • ,
  • E.V. Voss

      Affiliations

    • Dept. of Neurology, Hannover Medical School, Hannover, Germany
    • ,
  • B.C. Kieseier

      Affiliations

    • Dept. of Neurology, Heinrich-Heine-Universität, Düsseldorf, Germany
    • ,
  • M. Stangel

      Affiliations

    • Dept. of Neurology, Hannover Medical School, Hannover, Germany
    • Center for Systems Neurosciences, Hannover, Germany
    • Corresponding Author InformationCorresponding author. Dept. of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. Tel.: +49 511 5326676; fax: +49 511 5323115.

Received 12 June 2009 ,Revised 31 August 2009 ,Accepted 23 September 2009.

References 

  1. Agrawal S, Anderson P, Durbeej M, van Rooijen N, Ivars F, Opdenakker G, et al. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 2006;4:1007–1019
  2. Alby C, Ben Abdesselam O, Foglietti MJ, Beaudeux JL. Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood. Clin. Chim. Acta. 2002;1–2:183–186
  3. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol. Appl. Neurobiol. 1997;5:406–415
  4. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. U. S. A. 2008;50:19571–19578
  5. Barro C, Zaoui P, Morel F, Benhamou PY. Matrix metalloproteinase expression in rat pancreatic islets. Pancreas. 1998;4:378–382
  6. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci. Lett. 1995;3:223–226
  7. Chang CJ, Hsu LA, Ko YH, Chen PL, Chuang YT, Lin CY, et al. Thrombin regulates matrix metalloproteinase-9 expression in human monocytes. Biochem. Biophys. Res. Commun. 2009;2:241–246
  8. Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, et al. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. 1997;6:590–598
  9. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 1996;12:1194–1204
  10. Dehmel T, Janke A, Hartung HP, Goebel HH, Wiendl H, Kieseier BC. The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. Neurobiol. Dis. 2007;3:665–674
  11. Dubois B, Masure S, Hurtenbach U, Paemen L, Heremans H, van den OJ, et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J. Clin. Invest. 1999;11:1507–1515
  12. Esparza J, Kruse M, Lee J, Michaud M, Madri JA. MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity. FASEB J. 2004;14:1682–1691
  13. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin. Biochem. 2007;1–2:119–123
  14. Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J. Neurosci. Res. 1993;4:432–440
  15. Giulian D, Baker TJ. Characterization of ameboid microglia isolated from developing mammalian brain. J. Neurosci. 1986;8:2163–2178
  16. Gottschall PE. beta-Amyloid induction of gelatinase B secretion in cultured microglia: inhibition by dexamethasone and indomethacin. NeuroReport. 1996;18:3077–3080
  17. Gottschall PE, Deb S. Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation. 1996;2–3:69–75
  18. Gottschall PE, Yu X, Bing B. Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. J. Neurosci. Res. 1995;3:335–342
  19. Hartung HP, Kieseier BC. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol. 2000;2:140–147
  20. Humle JS, Sorensen PS. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J. Neurol. Sci. 2005;1–2:61–65
  21. Hurnaus S, Mueller-Felber W, Pongratz D, Schoser BG. Serum levels of matrix metalloproteinases-2 and -9 and their tissue inhibitors in inflammatory neuromuscular disorders. Eur. Neurol. 2006;4:204–208
  22. Jack C, Ruffini F, Bar-Or A, Antel JP. Microglia and multiple sclerosis. J. Neurosci. Res. 2005;3:363–373
  23. Jorgensen SH, Storm N, Jensen PE, Laursen H, Sorensen PS. IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions. Exp. Brain Res. 2007;4:462–469
  24. Jung K, Lein M, Laube C, Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin. Chim. Acta. 2001;1–2:241–244
  25. Kuhlmann T, Wendling U, Nolte C, Zipp F, Maruschak B, Stadelmann C, et al. Differential regulation of myelin phagocytosis by macrophages/microglia, involvement of target myelin, Fc receptors and activation by intravenous immunoglobulins. J. Neurosci. Res. 2002;2:185–190
  26. Larsen PH, Yong VW. The expression of matrix metalloproteinase-12 by oligodendrocytes regulates their maturation and morphological differentiation. J. Neurosci. 2004;35:7597–7603
  27. Larsen PH, Wells JE, Stallcup WB, Opdenakker G, Yong VW. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J. Neurosci. 2003;35:11127–11135
  28. Larsen PH, DaSilva AG, Conant K, Yong VW. Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J. Neurosci. 2006;8:2207–2214
  29. Lassmann H. New concepts on progressive multiple sclerosis. Curr. Neurol. Neurosci. Rep. 2007;3:239–244
  30. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 1996;6:846–852
  31. Liuzzi GM, Santacroce MP, Peumans WJ, Van Damme EJ, Dubois B, Opdenakker G, et al. Regulation of gelatinases in microglia and astrocyte cell cultures by plant lectins. Glia. 1999;1:53–61
  32. Liuzzi GM, Latronico T, Fasano A, Carlone G, Riccio P. Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult. Scler. 2004;3:290–297
  33. Liuzzi GM, Latronico T, Rossano R, Viggiani S, Fasano A, Riccio P. Inhibitory effect of polyunsaturated fatty acids on MMP-9 release from microglial cells—implications for complementary multiple sclerosis treatment. Neurochem. Res. 2007;12:2184–2193
  34. Mannello F, Tanus-Santos JE, Meschiari CA, Tonti GA. Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices. Anal. Biochem. 2008;1:56–63
  35. Mayer AM, Hall M, Fay MJ, Lamar P, Pearson C, Prozialeck WC, et al. Effect of a short-term in vitro exposure to the marine toxin domoic acid on viability, tumor necrosis factor-alpha, matrix metalloproteinase-9 and superoxide anion release by rat neonatal microglia. BMC. Pharmacol. 2001;7:
  36. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008;1:34–47
  37. Nuttall RK, Silva C, Hader W, Bar-Or A, Patel KD, Edwards DR, et al. Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia. Glia. 2007;5:516–526
  38. Oh LY, Larsen PH, Krekoski CA, Edwards DR, Donovan F, Werb Z, et al. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J. Neurosci. 1999;19:8464–8475
  39. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem. Biophys. Res. Commun. 1993;3:1175–1181
  40. Pul R, Nguyen D, Schmitz U, Marx P, Stangel M. Comparison of intravenous immunoglobulin preparations on microglial function in vitro: more potent immunomodulatory capacity of an IgM/IgA-enriched preparation. Clin. Neuropharmacol. 2002;5:254–259
  41. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia. 2002;3:279–291
  42. Rosenberg GA. Matrix metalloproteinases biomarkers in multiple sclerosis. Lancet. 2005;9467:1291–1293
  43. Shapiro S, Shoenfeld Y, Gilburd B, Sobel E, Lahat N. Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer. 2002;9:2032–2037
  44. Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology. 2004;11:2028–2033
  45. Stangel M, Compston A. Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors. J. Neuroimmunol. 2001;1–2:63–71
  46. Stangel M, Joly E, Scolding NJ, Compston DA. Normal polyclonal immunoglobulins (‘IVIg’) inhibit microglial phagocytosis in vitro. J. Neuroimmunol. 2000;1–2:137–144
  47. Tanuma N, Sakuma H, Sasaki A, Matsumoto Y. Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol. 2006;2:195–204
  48. Uhm JH, Dooley NP, Oh LY, Yong VW. Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia. 1998;1:53–63
  49. van Horssen J, Vos CM, Admiraal L, van Haastert ES, Montagne L, Van DV, et al. Matrix metalloproteinase-19 is highly expressed in active multiple sclerosis lesions. Neuropathol. Appl. Neurobiol. 2006;6:585–593
  50. Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL, et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult. Scler. 2004;1:89–91
  51. Warrington AE, Asakura K, Bieber AJ, Ciric B, Van KV, Kaveri SV, et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2000;12:6820–6825
  52. Wells GM, Catlin G, Cossins JA, Mangan M, Ward GA, Miller KM, et al. Quantitation of matrix metalloproteinases in cultured rat astrocytes using the polymerase chain reaction with a multi-competitor cDNA standard. Glia. 1996;4:332–340
  53. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat. Rev. Neurosci. 2005;12:931–944

PII: S0165-5728(09)00384-1

doi: 10.1016/j.jneuroim.2009.09.016

Journal of Neuroimmunology
Volume 217, Issue 1 , Pages 46-50 , 10 December 2009

Article Tools

* Image Usage & Resolution